# Long-Term Quality of Life in Patients With Metastatic Melanoma Treated With Checkpoint Inhibitors

> **NCT03326973** · — · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 107 (actual)

## Conditions studied

- Metastatic Melanoma

## Interventions

- **BEHAVIORAL:** EuroQoL EQ-5D-3L
- **BEHAVIORAL:** EORTC QLQ-C30
- **OTHER:** PRO-CTCAE
- **BEHAVIORAL:** Fatigue severity score questionnaire
- **BEHAVIORAL:** The COST
- **BEHAVIORAL:** Physician information

## Key facts

- **NCT ID:** NCT03326973
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-25
- **Primary completion:** 2020-12-14
- **Final completion:** 2020-12-14
- **Target enrollment:** 107 (ACTUAL)
- **Last updated:** 2020-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03326973

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03326973, "Long-Term Quality of Life in Patients With Metastatic Melanoma Treated With Checkpoint Inhibitors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03326973. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*